Oculis treats first patient in PIONEER-1 registrational trial of Privosegtor for optic neuritis

• Oculis began dosing patients in PIONEER-1, a registrational trial of Privosegtor for acute-onset optic neuritis.
• No new efficacy results were presented; the trial’s primary analysis is planned at Month 3, with follow-up through Month 12.
• Privosegtor is positioned as a potential neuroprotective treatment designed to improve vision recovery in optic neuritis.
• The program builds on earlier Phase 2 findings that supported FDA Breakthrough Therapy designation, with an acute MS relapse IND targeted for Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240400PRIMZONEFULLFEED1001258902) on August 24, 2026, and is solely responsible for the information contained therein.